This product will be manufactured at company’s Baddi plant in India.
Shares of Glenmark Pharma rose 1 percent intraday Tuesday as it has received ANDA approval for Clobetasol Propionate Spray.
Glenmark Pharmaceuticals Inc. USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Spray, 0.05%, the generic version of Clobex Spray, 0.05%, of Galderma Laboratories, L.P.
This product will be manufactured at company’s Baddi plant in India.
For the 12 month period ending January 2018, the Clobex Spray, 0.05% market achieved annual sales of approximately USD 30.5 million, as per IQVIA sales data.
Company’s current portfolio consists of 131 products authorized for distribution in the US marketplace and 63 ANDA’s pending approval with the USFDA.
At 12:03 hrs Glenmark Pharma was quoting at Rs 540.75, up Rs 1.45, or 0.27 percent on the BSE.
The share declined 38 percent in the last 1 year.
Posted by Rakesh Patil